MedTrace Logo

Myoelectric Robot-assisted Rehabilitation for the Upper Limb After Stroke

NCT02321254 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-07-02

No results posted yet for this study

Summary

The aim of this study is to assess the clinical effectiveness of the RehaARM-robot and to determine the feasibility of including robotic therapy in daily rehabilitation programmes, after stroke. Additionally, we aim to investigate the acceptance of this intervention from patients and therapists. A total of 10 patients will be recruited in this study, all the patients will receive 1 hour of standard therapy together with 45 min of robot therapy every day. The robot therapy will last 45 minutes, for 15 consecutive days within a maximum period of four weeks. Additional 15 minutes are required for placing surface electrodes on the shoulder and patient preparation. The study will include passive and active shoulder training of four movements: Horizontal abduction/adduction, abduction/adduction, internal/external rotation and flexion/extension. The passive part lasts 10 minutes and the active part 35 minutes.

Conditions

Interventions

DEVICE

The RehaARM-Robot

Robot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.

BEHAVIORAL

Standard rehabilitation therapy

Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities.

Sponsors & Collaborators

  • FerRobotics Compliant Robot GmbH, Linz, Austria

    collaborator UNKNOWN

  • IRCCS San Camillo, Venezia, Italy

    lead OTHER

Principal Investigators

  • Andrea Turolla, MSc · IRCCS San Camillo Hospital Foundation, Venice (Italy)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Austria
  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02321254 on ClinicalTrials.gov